secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAMED PHARMACEUTICALS INC. (ORMP)
CIK:        0001176309
Form:       8-K
Filed at:   2024-10-08T23:59:59+00:00
Accession:  0001213900-24-086214
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 1.01, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oramed restructures Scilex debt: exchanges $25M note for convertible notes, warrants, and royalty
--------------------------------------------------------------------------------

- Oramed exchanged $22.5M of its Scilex note for a $25M 5.5% convertible note due 2026 and 3.75M warrants at $1.09.
- Oramed exchanged $2.5M of note for a 4.0% royalty on global net sales of ZTlido and SP-103.
- Oramed entered binding term sheet for 50% JV with other investors to license lidocaine products outside US, investing $200K/year.
- Transactions closed Oct 8, 2024; proceeds repaid $12.5M of Oramed's note and eCapital credit facility.
- Scilex issued $50M aggregate convertible notes to Oramed and other investors; Oramed bought $22.5M of that.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024086214/0001213900-24-086214-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1176309/000121390024086214/ea0216936-8k_oramed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-086214

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer